Koichi Takaguchi
A5088307695- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Liver Disease and Transplantation
- Colorectal Cancer Treatments and Studies
- HIV/AIDS drug development and treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Inflammatory Biomarkers in Disease Prognosis
- Liver physiology and pathology
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Hepatitis Viruses Studies and Epidemiology
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Drug-Induced Hepatotoxicity and Protection
- Gastric Cancer Management and Outcomes
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Kagawa Prefectural Central Hospital
2016-2025
Hyogo University
2024
Second Affiliated Hospital of Xi'an Jiaotong University
2024
Kaohsiung Medical University
2024
National Sun Yat-sen University
2024
Asahi General Hospital
2023
National Hospital Organization Takasaki Medical Center
2023
University of Health Sciences
2021
Kagawa Prefectural College of Health Sciences
2021
Hudson Institute
2020
All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant 87 nonresponder chronic HCV genotype 1b infection were enrolled at 24 centers in Japan. Patients received daclatasvir 60 mg once daily plus asunaprevir 100 twice weeks. The primary endpoint...
<b><i>Background/Aim:</i></b> The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing Japan along the progression antiviral therapies and aging society. We evaluated usefulness modified albumin-bilirubin (ALBI) grade as a tool for assessment function. <b><i>Materials/Methods:</i></b> enrolled 6,649 naïve HCC treated from 2000 to 2017 divided them into training (Ehime Prefecture group: E...
We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u-HCC) by investigating real-world clinical features of patients.
Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins.
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
Aim Hepatic edema is manifested by ascites, lower limb and intolerable symptoms. Some patients insufficiently respond to the conventional diuretic therapy. Therefore, a novel therapeutic option required. We conducted phase 3 study confirm effect of tolvaptan on hepatic associated with liver cirrhosis. Methods I n our multicenter, randomized, double‐blind, placebo‐controlled trial, cirrhosis who showed insufficient response diuretics were randomly assigned 7‐day administration either at 7.5...
Abstract Background/Aim Presently, there are no therapeutic options for unresectable hepatocellular carcinoma (u‐HCC) patients who intolerant to sorafenib or regorafenib failure. There have been reports with detailed clinical findings of lenvatinib (LEN), a newly developed first‐line tyrosine kinase inhibitor (TKI), obtained in real‐world practice. We aimed elucidate the efficacy LEN. Materials/Methods From March August 2018, 105 u‐HCC were treated Following exclusion those started reduced...
Background & AimsThere is still a risk for hepatocellular carcinoma (HCC) development after eradication of hepatitis C virus (HCV) infection with antiviral agents. We investigated genetic factors associated the HCC in patients sustained virologic response (SVR) to treatment chronic HCV infection.MethodsWe obtained genomic DNA from 457 Japan SVR interferon-based 2007 through 2015. conducted genome-wide association study (GWAS), followed by replication analysis 79 candidate single nucleotide...
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir 5A (G/P), a coformulated once‐daily, all oral, ribavirin (RBV)‐free, direct‐acting antiviral regimen, was evaluated for safety efficacy in hepatitis C virus genotype 2 (GT2)–infected Japanese patients, including those with compensated cirrhosis. CERTAIN‐2 is phase 3, open‐label, multicenter study assessing the of G/P (300/120 mg) once daily treatment‐naive interferon ± RBV treatment–experienced patients without...
Abstract Background To assess the recent real-world changes in etiologies of liver cirrhosis (LC) Japan, we conducted a nationwide survey annual meeting Japan Society Hepatology (JSH). Methods We investigated LC patients accumulated from 68 participants 79 institutions ( N = 48,621). next assessed changing trends by analyzing cases which year diagnosis was available 45,834). further evaluated transition real number newly identified assessing data 36 hospitals with complete datasets for...
Lenvatinib (LEN) has recently become available as a first-line tyrosine-kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u-HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment options are needed. This retrospective study evaluated the therapeutic potential of LEN clinical practice.We enrolled 57 u-HCC treated with from March to June 2018. was given orally weighing <60 kg at 8 mg/day and 12 those ≥60 kg. Following exclusion...
We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN).We enrolled 84 u-HCC cases TKIs LEN from March 2018 January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage Liver Cancer Study Group Japan 6th (TNM-LCSGJ) II/III/IVa/IVb 12/30/5/37, Barcelona Clinic B/C 33:51). Clinical...
Abstract Background and aims Lenvatinib, a newly developed molecularly targeted agent, has become available for patients with unresectable hepatocellular carcinoma (HCC). Neutrophil‐to‐lymphocyte ratio (NLR) been reported to be associated poor outcomes in numerous malignancies. In this study, we investigated the impact of NLR on associating HCC treated lenvatinib. Methods A total 237 lenvatinib were included. We performed univariate multivariate analyses cohort. addition, clarified...
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed elucidate early responses Atez/Bev. Methods From September 2020 April 2021, 171 u‐HCC patients undergoing Atez/Bev were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative and...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...
Background/Aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use tumor markers as biomarkers monitoring treatment response is necessary. This study aimed to elucidate changes positive rates 3 available Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) uHCC...